Asklepios BioPharmaceutical Competitors and Similar CompaniesClear all
Asklepios BioPharmaceutical's competitors and similar companies include Ambrx, ProQR Therapeutics, Precigen and Mediphage Bioceuticals.
 Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. |  Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. |  ProQR Therapeutics ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases. |  Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. |  Mediphage Bioceuticals Mediphage Bioceuticals is a genetic medicine company developing a non-viral gene delivery vector platform. | |
Founding Date | Founding Date 2001 | Founding Date 2003 | Founding Date 2012 | Founding Date 1998 | Founding Date 2016 |
Type | Type Private | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Chapel Hill, US HQ Roslin, GB | Locations San Diego, US HQ | Locations Leiden, NL HQ Cambridge, US | Locations Germantown, US HQ Gent, BE Sioux Center, US | Locations Toronto, CA HQ |
Employees | Employees 5172% increase | Employees 70 | Employees 166 | Employees 601 | Employees 1023% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.8 b | Valuation ($) 281.8 m | Valuation ($) 246.6 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) €15.9m (FY, 2025) | Revenue (est.) $9.7m (FY, 2025) | Revenue (est.) N/A |
Net income | Net income N/A | Net income ($78m) (FY, 2022) | Net income (€42.2m) (FY, 2025) | Net income ($250.6m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 235m (about 7 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 3.5m (over 7 years ago) |
Total funding raised | Total funding raised $ 235m | Total funding raised $ 347.9m | Total funding raised $ 57.8m | Total funding raised $ 379m | Total funding raised $ 4.1m |
For sources of this data, please see the company profile
View Company Profiles
Ambrx
HQ
San Diego, US
Employees
70
Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code.
View companyProQR Therapeutics
HQ
Leiden, NL
Employees
166
ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases.
View companyPrecigen
HQ
Germantown, US
Employees
601
Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View companyMediphage Bioceuticals
HQ
Toronto, CA
Employees
10↓ 23% decrease
Mediphage Bioceuticals is a genetic medicine company developing a non-viral gene delivery vector platform.
View company